Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317600717> ?p ?o ?g. }
- W4317600717 endingPage "e0276892" @default.
- W4317600717 startingPage "e0276892" @default.
- W4317600717 abstract "Background Satisfactory treatment is often lacking for spasticity, a highly prevalent motor disorder in patients with spinal cord injury (SCI). Low concentrations of riluzole potently reduce the persistent sodium current, the post-SCI increase in which contributes to spasticity. The repurposing of this drug may therefore constitute a useful potential therapeutic option for relieving SCI patients suffering from chronic traumatic spasticity. Objective RILUSCI is a phase 1b–2b trial designed to assess whether riluzole is a safe and biologically effective means of managing spasticity in adult patients with traumatic chronic SCI. Methods In this multicenter double-blind trial, adults (aged 18–65 years) suffering from spasticity after SCI (target enrollment: 90 participants) will be randomly assigned to be given either a placebo or a recommended daily oral dose of riluzole for two weeks. The latter dose will be previously determined in phase 1b of the study by performing double-blind dose-finding tests using a Bayesian continuous reassessment method. The primary endpoint of the trial will be an improvement in the Modified Ashworth Score (MAS) or the Numerical Rating Score (NRS) quantifying spasticity. The secondary outcomes will be based on the safety and pharmacokinetics of riluzole as well as its impact on muscle spasms, pain, bladder dysfunction and quality of life. Analyses will be performed before, during and after the treatment and the placebo-controlled period. Conclusion To the best of our knowledge, this clinical trial will be the first to document the safety and efficacy of riluzole as a means of reducing spasticity in patients with chronic SCI. Trial registration The clinical trial, which is already in progress, was registered on the ClinicalTrials.gov website on August 9, 2016 under the registration number NCT02859792 . Trial sponsor Assistance Publique–Hôpitaux de Marseille." @default.
- W4317600717 created "2023-01-21" @default.
- W4317600717 creator A5003225431 @default.
- W4317600717 creator A5008589163 @default.
- W4317600717 creator A5009373255 @default.
- W4317600717 creator A5019272836 @default.
- W4317600717 creator A5036577995 @default.
- W4317600717 creator A5043534813 @default.
- W4317600717 creator A5073832013 @default.
- W4317600717 creator A5074414048 @default.
- W4317600717 creator A5080749949 @default.
- W4317600717 creator A5086914602 @default.
- W4317600717 date "2023-01-20" @default.
- W4317600717 modified "2023-10-14" @default.
- W4317600717 title "Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial" @default.
- W4317600717 cites W1857971518 @default.
- W4317600717 cites W1869228284 @default.
- W4317600717 cites W1966537571 @default.
- W4317600717 cites W1982312755 @default.
- W4317600717 cites W1986878360 @default.
- W4317600717 cites W1996362085 @default.
- W4317600717 cites W1999924211 @default.
- W4317600717 cites W2001798932 @default.
- W4317600717 cites W2008719375 @default.
- W4317600717 cites W2010378000 @default.
- W4317600717 cites W2014263842 @default.
- W4317600717 cites W2028360440 @default.
- W4317600717 cites W2029036884 @default.
- W4317600717 cites W2032541700 @default.
- W4317600717 cites W2032861450 @default.
- W4317600717 cites W2036085592 @default.
- W4317600717 cites W2039898366 @default.
- W4317600717 cites W2042497982 @default.
- W4317600717 cites W2055498642 @default.
- W4317600717 cites W2060715958 @default.
- W4317600717 cites W2060777786 @default.
- W4317600717 cites W2069317340 @default.
- W4317600717 cites W2073011580 @default.
- W4317600717 cites W2076108528 @default.
- W4317600717 cites W2078442444 @default.
- W4317600717 cites W2083044596 @default.
- W4317600717 cites W2083296081 @default.
- W4317600717 cites W2092415585 @default.
- W4317600717 cites W2093891530 @default.
- W4317600717 cites W2096059021 @default.
- W4317600717 cites W2099028265 @default.
- W4317600717 cites W2101138322 @default.
- W4317600717 cites W2116403843 @default.
- W4317600717 cites W2120681040 @default.
- W4317600717 cites W2122510396 @default.
- W4317600717 cites W2130873978 @default.
- W4317600717 cites W2139613967 @default.
- W4317600717 cites W2146182701 @default.
- W4317600717 cites W2154863411 @default.
- W4317600717 cites W2155307791 @default.
- W4317600717 cites W2155412494 @default.
- W4317600717 cites W2156969997 @default.
- W4317600717 cites W2161726634 @default.
- W4317600717 cites W2162299152 @default.
- W4317600717 cites W2163382042 @default.
- W4317600717 cites W2164949224 @default.
- W4317600717 cites W2166023752 @default.
- W4317600717 cites W2167615109 @default.
- W4317600717 cites W2256745758 @default.
- W4317600717 cites W2265704820 @default.
- W4317600717 cites W2299463430 @default.
- W4317600717 cites W2314689571 @default.
- W4317600717 cites W2325472161 @default.
- W4317600717 cites W2415035535 @default.
- W4317600717 cites W2587802115 @default.
- W4317600717 cites W2588211461 @default.
- W4317600717 cites W2901078211 @default.
- W4317600717 cites W2903188170 @default.
- W4317600717 cites W2913609543 @default.
- W4317600717 cites W2992901135 @default.
- W4317600717 cites W2994151676 @default.
- W4317600717 cites W3122535043 @default.
- W4317600717 cites W4247903468 @default.
- W4317600717 cites W836150979 @default.
- W4317600717 cites W2396406636 @default.
- W4317600717 doi "https://doi.org/10.1371/journal.pone.0276892" @default.
- W4317600717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36662869" @default.
- W4317600717 hasPublicationYear "2023" @default.
- W4317600717 type Work @default.
- W4317600717 citedByCount "0" @default.
- W4317600717 crossrefType "journal-article" @default.
- W4317600717 hasAuthorship W4317600717A5003225431 @default.
- W4317600717 hasAuthorship W4317600717A5008589163 @default.
- W4317600717 hasAuthorship W4317600717A5009373255 @default.
- W4317600717 hasAuthorship W4317600717A5019272836 @default.
- W4317600717 hasAuthorship W4317600717A5036577995 @default.
- W4317600717 hasAuthorship W4317600717A5043534813 @default.
- W4317600717 hasAuthorship W4317600717A5073832013 @default.
- W4317600717 hasAuthorship W4317600717A5074414048 @default.
- W4317600717 hasAuthorship W4317600717A5080749949 @default.
- W4317600717 hasAuthorship W4317600717A5086914602 @default.
- W4317600717 hasBestOaLocation W43176007171 @default.
- W4317600717 hasConcept C118552586 @default.